Peripheral Blood Stem Cells Versus Bone Marrow for Ablative Transplantation  by Eapen, Mary
G
B
c
m
d
P
f
i
m
P
a
t
b
P
d
m
i
t
m
y
g
g
P
l
w
D
t
c
a
a
T
w
T
Biology of Blood and Marrow Transplantation 13:76 (2006)
 2006 American Society for Blood and Marrow Transplantation
1083-8791/06/1301-0001$32.00/0
doi:10.1016/j.bbmt.2006.11.006
7raft Biology: Marrow Versus Peripheral
lood Versus Cord BloodRichard Champlin
t
rBone marrow, mobilized peripheral blood, and
ord blood are all sources of hematopoietic and im-Milwaukee, WI (e-mail: meapen@mcw.edu).
ransplantation (EBMT), examined long-term out-
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6ages for hematopoietic transplantation. This session
eviews current data and explores the role of each ofune cells. Each source has advantages and disadvan- these stem cell sources.
oi:10.1016/j.bbmt.2006.11.002
eripheral Blood Stem Cells Versus Bone Marrow
or Ablative Transplantation
Mary Eapen
Statistical Center, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin,Peripheral blood stem cells (PBSCs) are increas-
ngly being used for related and unrelated donor he-
atopoietic stem cell transplantation. Collection of
BSCs rather than bone marrow (BM) offers several
dvantages to the donor, including avoidance of anes-
hesia, hospitalization, and potential exposure to
lood products, although controlled comparisons of
BSC and BM donation do not indicate substantial
ifferences in serious adverse effects. There are nu-
erous reports, including randomized trials, compar-
ng recipient outcomes after PBSC and BM transplan-
ation from HLA-matched sibling donors, but the
edian follow-up of surviving patients is less than 3
ears. Most data support a higher risk of chronic
raft-versus-host disease with PBSCs than with BM
rafts, and some support a survival advantage with
BSCs in recipients of transplantation for advanced
eukemia. A convincing survival advantage for those
ith early leukemia has not yet been documented.
espite increasing numbers of unrelated donor PBSC
ransplantations, there are few reports describing out-
omes in these groups of patients and none supporting
survival advantage for acute or chronic leukemia
mong PBSC recipients.
The Center for International Blood and Marrow
ransplant Research (CIBMTR), in collaboration
ith the European Group for Blood and Marrowomes after PBSC and BM transplantation in patients
ith acute and chronic leukemia. The ﬁrst report with
median follow-up of 1 year showed higher chronic
VHD, lower transplantation-related mortality, and
reater leukemia-free survival in patients with ad-
anced leukemia at the time of transplantation [1].
ong-term follow-up data were obtained for 413 of
91 patients who were alive at the time of the initial
eport: 141 PBSC recipients and 272 BM recipients,
ith a median follow-up of more than 6 years [2].
onsistent with the initial report, chronic GVHD was
igure 1. Probability of leukemia-free survival in patients with
hronic leukemia after BM and PBSC transplants adjusted for
isease status at transplantation (N  number of evaluable patients;
 the 6-year rate of leukemia-free survival).
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PBSCs Versus BM for Ablative Transplantation 77ore frequent after PBSC transplantation than after
M transplantation (relative risk  1.65; P  .0001),
et relapse rates were similar in both groups. Leuke-
ia-free survival rates were higher after PBSC trans-
lantation than after BM transplantation for patients
ith advanced chronic myeloid leukemia (33% vs
5%) but lower for those in the ﬁrst chronic phase
41% vs 61%) due to higher rates of late transplanta-
ion-related mortality (Figure 1). Leukemia-free sur-
ival was similar after PBSC transplantation and BM
ransplantation for acute leukemia (Figure 2). These
ata represent the early experience with PBSC grafts.
evertheless, this is the ﬁrst report describing long-
erm outcomes after PBSC transplantation and indi-
ates that although patients with advanced chronic
eukemia may beneﬁt from PBSC grafts, those with
cute leukemia or early chronic leukemia may not.
hese ﬁndings should be validated with long-term
ollow-up of patients enrolled in randomized studies.
Because few studies have examined the beneﬁts of
sing PBSC grafts versus BM grafts for unrelated
onor transplantation, the CIBMTR compared out-
omes after 451 PBSC transplantations and 781 BM
ransplantations in adults with leukemia and myelo-
ysplastic syndrome followed for a median of 3 years
fter transplantation [3]. Rates of grades 2-4 acute
VHD (56% vs 46%; P   .001), but not grade 3-4
cute GVHD, were higher after PBSC transplantation
igure 2. Probability of leukemia-free survival in patients with
cute leukemia after BM and PBSC transplants adjusted for disease
tatus at transplantation (N  number of evaluable patients; % 
he 6-year rate of leukemia-free survival).han after BM transplantation. Chronic GVHD was
ore frequent with PBSC transplantation than with
M transplantation (54% vs 40%; P  .001). The
-year probabilities of treatment-related mortality,
eukemia recurrence, leukemia-free survival, and over-
ll survival were similar in the 2 groups; 3-year leuke-
ia-free survival rates were 29% after PBSC transplan-
ation and 31% after BM transplantation (Figure 3).
nlike for results after HLA-matched sibling donor
BSC transplantation, we were unable to identify a sur-
ival advantage in patients with advanced leukemia. The
igher rate of chronic GVHD after PBSC transplanta-
ion and, consequently, more frequent late adverse
vents warrant extended follow-up of these PBSC recip-
ents, which is planned.
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